HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leigh, R J Articles by Tomsak, R L Search for Related Content PubMed PubMed Citation Articles by Leigh, R J Articles by Tomsak, R L

Drug treatments for eye movement disorders

Department of Neurology, Veterans Affairs Medical Center, and University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA

Correspondence to:
Correspondence to:
Dr R John Leigh, Department of Neurology, University Hospitals, 11100 Euclid Avenue, Cleveland, Ohio 44106–5040, USA;
rjl4@po.cwru.edu

Keywords: nystagmus; opsoclonus; gabapentin; baclofen

The first 150 words of the full text of this article appear below.

PATHOGENESIS OF ABNORMAL EYE MOVEMENTS AND THEIR VISUAL CONSEQUENCES
The modern rationale for the treatment of abnormal eye movements rests on current concepts of the neurobiology of ocular motility and vision.¹ In order to see clearly the details in our visual world, images must be held quite still upon the retina, especially the central, foveal part, which has the highest density of photoreceptors. In order to read, which concerns detection of high spatial frequencies, image motion should ideally be less than about 5°/s.² If image drift substantially exceeds this limit, visual acuity will decline and the illusion that the world is moving (oscillopsia) may be experienced. Normally, three main mechanisms hold gaze (the line of sight) steady, so that our view of the world is clear and stable.² The first is the vestibulo-ocular reflex, by which the motion detectors of the inner ear initiate eye movements to compensate for head perturbations, such as occur during locomotion. . . . [Full text of this article]

This article has been cited by other articles:

				P. Feys, W. Helsen, B. Nuttin, A. Lavrysen, P. Ketelaer, S. Swinnen, and X. Liu Unsteady gaze fixation enhances the severity of MS intention tremor Neurology, January 8, 2008; 70(2): 106 - 113. [Abstract] [Full Text] [PDF]

				D. V Keen Conduct disorders and us: from heart sink to heart warming? Arch. Dis. Child., October 1, 2007; 92(10): 838 - 841. [Full Text] [PDF]

				G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]

				S Glasauer, R Kalla, U Buttner, M Strupp, and T Brandt 4-aminopyridine restores visual ocular motor function in upbeat nystagmus J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 451 - 453. [Abstract] [Full Text] [PDF]

				R. Kalla, S. Glasauer, F. Schautzer, N. Lehnen, U. Buttner, M. Strupp, and T. Brandt 4-Aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain Neurology, April 13, 2004; 62(7): 1228 - 1229. [Full Text] [PDF]

				A. R. Pachner, J. Oger, and J. Palace The measurement of antibodies binding to IFN{beta} in MS patients treated with IFN{beta} Neurology, November 11, 2003; 61(90095): S18 - 20. [Full Text]

				R. J. Leigh Potassium channels, the cerebellum, and treatment for downbeat nystagmus Neurology, July 22, 2003; 61(2): 158 - 159. [Full Text] [PDF]